L. Jacobasch

发表

CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study.

B. Dörken, R. Grützmann, H. Oettle, 2015 .

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.

T. Friede, R. Grützmann, C. Rödel, 2021, JAMA oncology.

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int‐1‐risk MDS patients: Results of the phase II KALLISTO trial

Jie Jin, N. Gattermann, L. Jacobasch, 2018, European journal of haematology.

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.

S. Kubicka, A. Hinke, M. Sinn, 2022, JAMA oncology.

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

M. Stauch, J. Trojan, R. Hofheinz, 2020, International journal of cancer.

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

C. Bokemeyer, A. Hinke, A. Stein, 2020, BMC Cancer.

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.

T. Friede, R. Grützmann, J. Weitz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial

R. Grützmann, W. Uhl, W. Hohenberger, 2019, BMC Cancer.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).

V. Heinemann, S. Kasper, C. Junghanss, 2021, Journal of Clinical Oncology.

Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera

H. Tesch, F. Heidel, M. Reiser, 2021, Journal of Cancer Research and Clinical Oncology.

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

M. Beksac, M. Dimopoulos, S. Lonial, 2020, The Lancet. Oncology.

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.

B. Dörken, R. Grützmann, H. Oettle, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial

U. Neumann, R. Grützmann, W. Uhl, 2020, Strahlentherapie und Onkologie.

Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.

C. Théodore, Stefano Kim, C. Papandreou, 2015, Clinical genitourinary cancer.

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

C. Bokemeyer, A. Hinke, A. Stein, 2020, BMC Cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia

M. Hallek, U. Kaiser, A. Fink, 2021, American journal of hematology.

53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)

A. Saborowski, D. Pink, E. Goekkurt, 2022, Annals of Oncology.

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial

R. Grützmann, W. Uhl, W. Hohenberger, 2019, BMC Cancer.

Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315)

E. Gallmeier, T. Ettrich, L. Fischer von Weikersthal, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).

K. Kaczirek, A. Kiani, M. Karthaus, 2022, European journal of cancer.

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial

L. Jacobasch, T. Geer, S. Isfort, 2023, Annals of Hematology.